🇺🇸 FDA
Patent

US 10716793

Treprostinil administration by inhalation

granted A61KA61K31/192A61K31/557

Quick answer

US patent 10716793 (Treprostinil administration by inhalation) held by United Therapeutics Corporation expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/192, A61K31/557, A61K9/0078, A61K9/008